Roche Xeloda Gets Approved For Stomach Cancer In China
This article was originally published in PharmAsia News
Executive Summary
Shanghai Roche Pharmaceuticals has received China's State FDA approval for its targeting chemotherapy drug Xeloda (capecitabine) to treat progressive gastric cancer. Research data show that chemotherapy is an important approach for treating gastric cancer, especially for intermediate and advanced cancer. Xeloda is an oral chemotherapy drug first approved in the U.S. It was launched in 2001 for use in China for treating colorectal cancer and metastatic breast cancer. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.